Clinical trial NCT00715078: To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
Official title: A Randomized, Multicenter, Single Blind Study in Men With Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prostate Cancer
Keywords: prostate cancer
prostate
immune therapy
immunotherapy
vaccine
dendritic cells
antigen-presenting cells
antigen presenting cells
cancer vaccine
prostate specific antigen (PSA)
prostatic adenocarcinoma
Lead sponsor: Dendreon
Sponsor class: INDUSTRY
First posted: 2008-07-15
Enrollment: 122
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen

Detailed description: This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with 1 of 3 different concentrations of PA2024 antigen The primary purpose of this study is to compare the changes in CD54 upregulation between each of these 3 groups of subjects.

Eligibility criteria: Inclusion Criteria:

For a subject to be eligible for participation in this study, all of the following criteria must be satisfied.

* Histologically documented adenocarcinoma of the prostate.
* Metastatic disease.
* Progressive androgen independent castrate resistant prostate cancer.
* Serum PSA ≥ 5.0 ng/mL.
* Life expectancy of ≥ 6 months.
* Castrate level of testosterone (\< 50 ng/dL) achieved via medical or surgical castration.
* Men ≥ 18 years of age.
* Adequate hematologic, renal and liver function.

Exclusion Criteria:

A subject will not be eligible for participation in this study if any of the following criteria apply.

* The presence of known lung, liver, or brain metastases, malignant pleural effusions, or malignant ascites.
* A requirement for treatment with opioid analgesics for any reason within 21 days prior to registration.
* Moderate to severe disease related pain.
* Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2.
* Use of non-steroidal antiandrogens within 6 weeks of registration.
* Anti-androgen withdrawal response.
* Treatment with chemotherapy within 3 months of registration.
* More than 2 chemotherapy regimens prior to registration.
* Initiation or discontinuation of bisphosphonate therapy within 28 days prior to registration.
* Treatment with any of the following medications or interventions within 28 days of registration:

  * Systemic corticosteroids,
  * External beam radiation therapy or surgery,
  * Dietary and herbal supplements, as well as alternative treatments that have evidence of hormonal and/or anticancer properties (e.g., prostate cancer (PC) -SPES or PC-SPEC) and saw palmetto,
  * Megestrol acetate (Megace®), diethylstilbesterol (DES), or cyproterone acetate, ++Ketoconazole,
  * 5-alpha-reductase inhibitors,
  * High dose calcitriol \[1,25(OH)2Vitamin D\] (i.e., \> 0.5 mcg/day).
* Any other systemic therapy for prostate cancer (except for medical castration).
* Treatment with any investigational vaccine within 2 years of registration or treatment with any other investigational product within 28 days of registration.
* Participation in any previous study involving sipuleucel-T, regardless of whether the subject received sipuleucel-T (APC8015) or placebo.
* Known pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography \> 50%) or spinal cord compression.
* A history of stage III or greater cancer, excluding prostate cancer. Basal or squamous cell skin cancers must have been adequately treated and the subject must be disease-free at the time of registration. Subjects with a history of stage I or II cancer must have been adequately treated and been disease-free for ≥ 3 years at the time of registration.
* A requirement for systemic immunosuppressive therapy for any reason.
* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to sipuleucel-T or granulocyte-macrophage colony-stimulating factor.
* Any infection requiring parenteral antibiotic therapy or causing fever (temp \> 100.5°F or \> 38.1°C) within 1 week prior to registration.
* Any medical intervention or other condition which, in the opinion of the Principal Investigator or the Dendreon Medical Monitor, could compromise adherence with study requirements or otherwise compromise the study's objectives.

Primary outcomes:
measure: Cumulative CD54 Upregulation Ratio Between Each of the Cohorts.
timeFrame: Baseline, Months 2, 4 and 6.
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UCSD Moores Cancer Center
state: California
city: San Diego
country: United States
facility: Sharp Clinical Oncology Research
state: California
city: Washington, D.C.
country: United States
facility: Georgetown University Medical Center
state: District of Columbia
city: Indianapolis
country: United States
facility: Indiana University
state: Indiana
city: New York
country: United States
facility: Mount Sinai School of Medicine
state: New York
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Portland
country: United States
facility: Providence Medical Center
state: Oregon
city: Portland
country: United States
facility: Kaiser Permanente
state: Oregon
city: Portland
country: United States
facility: Northwest Cancer Specialists
state: Oregon
city: Norfolk
country: United States
facility: Urology of Virginia, Sentara Medical Group
state: Virginia
city: Seattle
country: United States
facility: Virginia Mason Medical Center Urology and Renal Transplantation
state: Washington
city: Seattle
country: United States
facility: Seattle Cancer Care Alliance
state: Washington
Study officials:
affiliation: Valeant Pharmaceuticals North America LLC
name: Robert Israel, MD
role: STUDY_DIRECTOR
References: